Charles Schwab
AURA icon

Charles Schwab’s Aura Biosciences AURA Stock Holding History

Charles Schwab’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
163,156
+66,017
+68% +$472K ﹤0.01% 2967
2026
Q1 		$650K Sell
97,139
-37,924
-28% -$218K ﹤0.01% 3027
2025
Q4 		$736K Buy
135,063
+115
+0.1% +$683 ﹤0.01% 3026
2025
Q3 		$834K Buy
134,948
+15,297
+13% +$100K ﹤0.01% 3014
2025
Q2 		$749K Sell
119,651
-18,815
-14% -$110K ﹤0.01% 2994
2025
Q1 		$811K Hold
138,466
– – ﹤0.01% 2910
2024
Q4 		$1.14M Buy
138,466
+110
+0.1% +$1.03K ﹤0.01% 2873
2024
Q3 		$1.23M Buy
138,356
+3,612
+3% +$31K ﹤0.01% 2857
2024
Q2 		$1.02M Buy
134,744
+28,500
+27% +$209K ﹤0.01% 2929
2024
Q1 		$834K Buy
106,244
+14,796
+16% +$123K ﹤0.01% 2850
2023
Q4 		$810K Buy
91,448
+18,725
+26% +$159K ﹤0.01% 2902
2023
Q3 		$652K Hold
72,723
– – ﹤0.01% 2947
2023
Q2 		$898K Buy
72,723
+9,310
+15% +$99.5K ﹤0.01% 2809
2023
Q1 		$588K Buy
63,413
+15,606
+33% +$162K ﹤0.01% 2898
2022
Q4 		$502K Buy
47,807
+804
+2% +$10.2K ﹤0.01% 3004
2022
Q3 		$852K Buy
47,003
+3,994
+9% +$60.5K ﹤0.01% 2836
2022
Q2 		$610K Buy
43,009
+27,630
+180% +$457K ﹤0.01% 2995
2022
Q1 		$339K Buy
15,379
+3,557
+30% +$67.8K ﹤0.01% 3188
2021
Q4 		$201K Buy
+11,822
New +$211K ﹤0.01% 3358

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Charles Schwab's AURA Position: Q2 2026 in Review

Charles Schwab increased its Aura Biosciences (AURA) stake by 68% in Q2 2026, buying an estimated $472K and bringing the position to 163,156 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2967.

Charles Schwab first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.23M in Q3 2024. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Charles Schwab held 163,156 shares of Aura Biosciences worth $1.16M as of Q2 2026.
  • Charles Schwab bought 66,017 Aura Biosciences shares in Q2 2026, an estimated $472K.
  • Aura Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2967 holding.
  • Charles Schwab first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Charles Schwab's Aura Biosciences position peaked at $1.23M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.